TY  - JOUR
T1  - Efficacy and safety of vigabatrin as an initial therapy for tuberous sclerosis-associated infantile spasms
A1  - Naim Zeka
A1  - Haki Jashari
A1  - Ramush Bejiqi
A1  - Blenda Zeka
A1  - Leonore Zogaj
A1  - Arlinda Maloku
JF  - Journal of Advanced Pharmacy Education and Research
JO  - J Adv Pharm Educ Res
SN  - 2249-3379
Y1  - 2023
VL  - 13
IS  - 2
DO  - 10.51847/aOyVGONwGi
SP  - 124
EP  - 127
N2  - Tuberous sclerosis Complex (TSC) is a genetic disorder characterized by the formation of benign tumors in multiple organs, including the brain. Infantile spasms (IS) are a common seizure type that can occur in children with TSC and can lead to developmental delays and cognitive impairment if left untreated. Vigabatrin is an antiepileptic drug that has been shown to be effective in treating IS, but its efficacy and safety in TSC-afflicted children are not well understood. Our study intended to investigate the efficacy and safety of vigabatrin in treating infantile spasms in children with tuberous sclerosis. A retrospective analysis of medical records was conducted in a tertiary hospital and identified 25 children with tuberous sclerosis who had been diagnosed with infantile spasms and treated with vigabatrin. We found that vigabatrin was effective in controlling infantile spasms in 84% of patients, with a significant reduction in seizure frequency and improvement in developmental outcomes. However, we also observed a high incidence of adverse events, particularly visual field defects. Our study highlights the potential benefits and risks of vigabatrin as a treatment option for infantile spasms in children with tuberous sclerosis and underscores the importance of careful monitoring for adverse effects. More investigation is required to improve the understanding of the drug’s long-term safety and efficacy in this population‎.
UR  - https://japer.in/article/efficacy-and-safety-of-vigabatrin-as-an-initial-therapy-for-tuberous-sclerosis-associated-infantile-toqripvzad0yi3p
ER  -